Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Pain Med. 2011 Aug 3;12(9):1406–1413. doi: 10.1111/j.1526-4637.2011.01203.x

Table 2.

Efficacy outcome measures: Tender points (# quadrants of Pain) Across the Study

ID Baseline
Average		 Acute
Study
End		 After 5
Months
of Stim.		 After 8
Months
of Stim.		 After 11
Months of
Stim.
102 12 (5) 9 (5) 5 (4) 10 (5) 14 (5)
104 18 (5) 2 (4) 4 (5) 1 (1) 8 (2)
105 14.5 (5) 6 (4) STOP STOP EXPLANT
106 18 (5) 11 (5) 8 (0) 5 (2) 7 (3)
107 16 (5) 12 (5) 8 (5) 6 (3) 3 (3)
108 17 (5) 4 (1) 4 (3) 7 (0) 6 (0)
111 15.5 (5) 0 (1)
 8 (5) 9 (5) 9 (4)
114 18 (5) 16 (5) 16 (5) 8 (4) 13 (5)
115 18 (5) DEVICE PROBLEM THEN SIDE EFFECTS→ STOP
117 18 (5) 18 (5) 5 (0) 2 (2) 5 (2)
118 13.5 (5) STUDY VIOLATION; EXCLUDED
119 18 (5) 18 (5) 18 (5) 18 (5) 18 (5)
121 18 (5) 18 (4) 18 (5) 18 (3) 18 (5)
124 15 (5) 15 (4) 14 (4) 11 (4) 15 (4)

graphic file with name nihms305993ig1.jpg

Light grey filled cell indicates MCID+

Thick black outlined cell indicates no longer fulfilling EITHER widespread pain OR tenderness criteria for FM

Dark grey filled cell indicates patient who at last visit did not fulfill tenderness criterion for FM